Chronic bacterial prostatitis
Chronic bacterial prostatitis (CBP) is a recurrent, debilitating infection of the prostate, most often caused by uropathogenic E. coli (frequently ESBL-producing and fluoroquinolone-resistant) and Enterococcus faecalis. It is notoriously hard to cure because the prostate is a poorly vascularized, biofilm-rich sanctuary site that most antibiotics penetrate weakly, so relapse after oral therapy is the rule rather than the exception. Bacteriophages are well suited to this niche: they are strain-specific lytic agents that self-amplify at the infection site, actively penetrate and disrupt biofilms, retain activity against multidrug-resistant strains, and can be combined with antibiotics for synergy. This combination of biofilm activity, deep-tissue self-propagation, and resistance-independent killing is precisely what conventional antibiotics lack in the prostate.
How phages act here
Mechanism
Phages bind specific surface receptors on the target strain (e.g., LPS or pili on uropathogenic E. coli, or cell-wall structures on E. faecalis), inject their genome, hijack the host, and lyse the cell — killing is strain-specific, which spares the surrounding microbiota but requires pre-treatment susceptibility ("phagogram") testing and usually a multi-phage cocktail to cover heterogeneous and evolving isolates. Phages and their depolymerase enzymes degrade the exopolysaccharide matrix of prostatic biofilms, exposing sessile and persister bacteria that tolerate antibiotics, and because phages replicate at the infection focus they can reach titers inside low-vascularity tissue that drugs cannot. Phage-antibiotic synergy (PAS) is a central mechanism here: sub-lethal antibiotics can boost phage production and, conversely, phages can re-sensitize resistant bacteria — demonstrated for an ESBL E. coli prostatitis isolate where SES/PYO phage cocktails enhanced doxycycline killing in vitro despite the strain being doxycycline-resistant. Engineered approaches push this further: Locus Biosciences' LBP-EC01 is a six-phage cocktail armed with a CRISPR-Cas3 construct that shreds the E. coli genome, adding a sequence-targeted killing mechanism on top of natural lysis; phage-derived endolysins (e.g., the Ef11 lysin against E. faecalis) act as standalone "enzybiotics" that hydrolyze the bacterial cell wall directly.
Where it stands
Current evidence
As of 2026 the evidence for phages in CBP specifically is at the case-report and translational stage — promising and growing, but with no completed randomized controlled trial in this exact indication. Multiple peer-reviewed case reports document cure of antibiotic-refractory CBP: a 2023 report (Johri et al.) cleared a recurrent E. coli prostatitis after two courses of Eliava Institute phage cocktails following 5 years of failed antibiotics; a 2023 report (Stevens et al.) resolved an antibiotic-resistant E. faecalis CBP using a phage-derived endolysin (Ef11 lysin); and a 2025 report (Cesta et al., Int J Antimicrob Agents) cured an ESBL E. coli prostatitis with oral SES + PYO phage cocktails plus doxycycline, backed by in vitro phage-antibiotic synergy testing against five E. coli isolates. Much of the clinical experience comes from the Eliava Phage Therapy Center (Tbilisi) and Vitalis Phage Therapy under compassionate/magistral use. The strongest registered-trial evidence for the E. coli urinary target is adjacent rather than prostatitis-specific: Locus Biosciences' CRISPR-Cas3 phage LBP-EC01 reported positive Part 1 Phase 2 results in The Lancet Infectious Diseases (2024) in the ELIMINATE trial (NCT05488340), showing rapid, durable E. coli reduction and symptom resolution; an earlier randomized, placebo-controlled PYO-phage trial in urinary infection around prostate surgery (NCT03140085, Balgrist University Hospital/Eliava) has completed. A 2025 systematic review (Larcher et al.) of phage therapy across 12 UTI studies (89 patients) found it generally well tolerated with variable but sometimes complete efficacy, while flagging unresolved dosing and the need for randomized trials.
Evidence confidence: medium
The data
Key studies & trials
- Cesta N, Fusco A, Ferretti C, et al. Bacteriophage-enhanced doxycycline activity against Escherichia coli in chronic bacterial prostatitis. International Journal of Antimicrobial Agents. 2025;66(4):107571. (Case report of ESBL E. coli CBP cured with oral SES + PYO phage cocktails plus doxycycline, with in vitro phage-antibiotic synergy data.) ↗
- Johri AV, Johri P, Hoyle N, Nadareishvili L, Pipia L, Nizharadze D. Case report: Successful treatment of recurrent E. coli infection with bacteriophage therapy for patient suffering from chronic bacterial prostatitis. Frontiers in Pharmacology. 2023;14:1243824. (Recurrent E. coli CBP resolved after two courses of Eliava Institute phage therapy following 5 years of failed antibiotics.) ↗
- Stevens RH, Zhang H, Kajsik M, et al. Successful use of a phage endolysin for treatment of chronic pelvic pain syndrome/chronic bacterial prostatitis. Frontiers in Medicine. 2023;10:1238147. (First reported cure of antibiotic-resistant Enterococcus faecalis CBP using the bacteriophage Ef11-derived endolysin.) ↗
- Kim P, Sanchez AM, Penke TJR, et al. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial. The Lancet Infectious Diseases. 2024;24(12):1319-1332. (Phase 2; ClinicalTrials.gov NCT05488340; engineered anti-E. coli phage cocktail, the registered-trial benchmark for the urinary E. coli target.) ↗
Who is working on it
Programs & centers
The possibility
If susceptibility-matched phage cocktails and engineered CRISPR-phages move from compassionate-use case reports into randomized prostatitis trials, CBP could become a leading proof-of-concept for precision antibacterials — a urologist could phenotype a man's E. coli or Enterococcus strain, assemble a personalized cocktail (or a genome-targeting CRISPR-Cas3 phage), and deliver it orally or by intraprostatic/intravesical instillation to crack open biofilms that have defied antibiotics for years. Pairing phages with low-dose antibiotics to exploit phage-antibiotic synergy and re-sensitization could convert today's "incurable" relapsing cases into durable cures while sparing the urinary and gut microbiome. The same playbook — phages plus endolysins as enzybiotics — points toward off-the-shelf and personalized products that finally give clinicians a microbiome-sparing tool for one of urology's most stubborn chronic infections.